Allergan Eyes 2017 Tear-Stimulator Launch With Oculeve Buy
This article was originally published in The Gray Sheet
Executive Summary
The $125-million-plus-milestons deal for the Stanford spinout gives Allergan nasal neurostimulation device for tear production that could be ready for U.S. launch in 2017 and a second, earlier stage dry-eye therapy.